At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 79 enrolled
Drug / intervention
Xenical + behavioral intervention +1 moredrug
Likely dose
Xenical + behavioral intervention 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons
In Brief
A Phase 4 clinical trial evaluating Xenical + behavioral intervention and Behavioral intervention + placebo for Obesity and Binge Eating. Completed, enrolled 79 participants across 2 sites.
Detailed Summary
This is a research study designed to examine the effectiveness of an obesity medication (orlistat) given in addition to behavioral weight loss therapy. Participants will be obese monolingual (Spanish-speaking only) men and women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Binge Eating
CountriesUnited States
CollaboratorsDonaghue Medical Research Foundation
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionDec 2010
TodayJul 2026
First PostedAug 16, 2007
Enrollment StartAug 1, 2007
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.9 years ago
Interventions
Xenical + behavioral interventiondrug
120 mg TID; Behavioral weight loss in Spanish
Behavioral intervention + placebobehavioral
Behavioral weight loss treatment in Spanish Placebo TID